Literature DB >> 15213111

Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen.

Marcel Hijnen1, Frits R Mooi, Pieter G M van Gageldonk, Peter Hoogerhout, Audrey J King, Guy A M Berbers.   

Abstract

Bordetella pertussis is reemerging in several countries with a traditionally high vaccine uptake. An analysis of clinical isolates revealed antigenic divergence between vaccine strains and circulating strains with respect to P.69 pertactin. Polymorphisms in P.69 pertactin are mainly limited to regions comprised of amino acid repeats, designated region 1 and region 2. Region 1 flanks the RGD motif, which is involved in adherence. Although antibodies against P.69 pertactin are implicated in protective immunity, little is known about the structure and location of its epitopes. Here we describe the identification by pepscan analysis of the locations of mainly linear epitopes recognized by human sera and mouse monoclonal antibodies (MAbs). A total of 24 epitopes were identified, and of these only 2 were recognized by both MAbs and human antibodies in serum. A number of immunodominant epitopes were identified which were recognized by 78 to 93% of the human sera tested. Blocking experiments indicated the presence of high-avidity human antibodies against conformational epitopes. Human antibodies against linear epitopes had much lower avidities, as they were unable to block MAbs. Pepscan analyses revealed several MAbs which bound to both region 1 and region 2. The two regions are separated by 289 amino acids in the primary structure, and we discuss the possibility that they form a single conformational epitope. Thus, both repeat regions may serve to deflect the immune response targeted to the functional domain of P.69 pertactin. This may explain why the variation in P.69 pertactin is so effective, despite the fact that it is limited to only two small segments of the molecule.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15213111      PMCID: PMC427433          DOI: 10.1128/IAI.72.7.3716-3723.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  32 in total

Review 1.  Overview of recent clinical trials of acellular pertussis vaccines.

Authors:  E Miller
Journal:  Biologicals       Date:  1999-06       Impact factor: 1.856

2.  Mimotopes: realization of an unlikely concept.

Authors:  R H Meloen; W C Puijk; J W Slootstra
Journal:  J Mol Recognit       Date:  2000 Nov-Dec       Impact factor: 2.137

3.  A model based evaluation of the 1996-7 pertussis epidemic in The Netherlands.

Authors:  M van Boven; H E de Melker; J F Schellekens; M Kretzschmar
Journal:  Epidemiol Infect       Date:  2001-08       Impact factor: 2.451

4.  Bordetella pertussis protein pertactin induces type-specific antibodies: one possible explanation for the emergence of antigenic variants?

Authors:  Qiushui He; Johanna Mäkinen; Guy Berbers; Frits R Mooi; Matti K Viljanen; Heikki Arvilommi; Jussi Mertsola
Journal:  J Infect Dis       Date:  2003-03-26       Impact factor: 5.226

5.  Sequence variation in pertussis S1 subunit toxin and pertussis genes in Bordetella pertussis strains used for the whole-cell pertussis vaccine produced in Poland since 1960: efficiency of the DTwP vaccine-induced immunity against currently circulating B. pertussis isolates.

Authors:  Anna Gzyl; Ewa Augustynowicz; Grzegorz Gniadek; Daniel Rabczenko; Grazyna Dulny; Janusz Slusarczyk
Journal:  Vaccine       Date:  2004-06-02       Impact factor: 3.641

6.  Structure of Bordetella pertussis virulence factor P.69 pertactin.

Authors:  P Emsley; I G Charles; N F Fairweather; N W Isaacs
Journal:  Nature       Date:  1996-05-02       Impact factor: 49.962

7.  Serum IgA antibody to Bordetella pertussis as an indicator of infection.

Authors:  J Nagel; E J Poot-Scholtens
Journal:  J Med Microbiol       Date:  1983-11       Impact factor: 2.472

8.  Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity.

Authors:  A J King; G Berbers; H F van Oirschot; P Hoogerhout; K Knipping; F R Mooi
Journal:  Microbiology       Date:  2001-11       Impact factor: 2.777

9.  Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data.

Authors:  H E de Melker; J F Schellekens; S E Neppelenbroek; F R Mooi; H C Rümke; M A Conyn-van Spaendonck
Journal:  Emerg Infect Dis       Date:  2000 Jul-Aug       Impact factor: 6.883

10.  Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence?

Authors:  F R Mooi; I H van Loo; A J King
Journal:  Emerg Infect Dis       Date:  2001       Impact factor: 6.883

View more
  8 in total

1.  Pathogen adaptation under imperfect vaccination: implications for pertussis.

Authors:  Michiel van Boven; Frits R Mooi; Joop F P Schellekens; Hester E de Melker; Mirjam Kretzschmar
Journal:  Proc Biol Sci       Date:  2005-08-07       Impact factor: 5.349

Review 2.  Diversity-generating retroelements.

Authors:  Bob Medhekar; Jeff F Miller
Journal:  Curr Opin Microbiol       Date:  2007-08-20       Impact factor: 7.934

3.  Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694.

Authors:  Emmanuelle Laffly; Ludivine Danjou; Florence Condemine; Dominique Vidal; Emmanuel Drouet; Marie-Paule Lefranc; Chantal Bottex; Philippe Thullier
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  Pertactin is required for Bordetella species to resist neutrophil-mediated clearance.

Authors:  Carol S Inatsuka; Qian Xu; Ivan Vujkovic-Cvijin; Sandy Wong; Scott Stibitz; Jeff F Miller; Peggy A Cotter
Journal:  Infect Immun       Date:  2010-04-26       Impact factor: 3.441

5.  Fast, antigen-saving multiplex immunoassay to determine levels and avidity of mouse serum antibodies to pertussis, diphtheria, and tetanus antigens.

Authors:  Rachel M Stenger; Mieke Smits; Betsy Kuipers; Sabine F M Kessen; Claire J P Boog; Cécile A C M van Els
Journal:  Clin Vaccine Immunol       Date:  2011-02-16

6.  High-throughput identification of new protective antigens from a Yersinia pestis live vaccine by enzyme-linked immunospot assay.

Authors:  Bei Li; Lei Zhou; JingYu Guo; Xiaoyi Wang; Bin Ni; Yuehua Ke; Ziwen Zhu; Zhaobiao Guo; Ruifu Yang
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

Review 7.  Pertussis: Microbiology, Disease, Treatment, and Prevention.

Authors:  Paul E Kilgore; Abdulbaset M Salim; Marcus J Zervos; Heinz-Josef Schmitt
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

8.  Selective ligand recognition by a diversity-generating retroelement variable protein.

Authors:  Jason L Miller; Johanne Le Coq; Asher Hodes; Roman Barbalat; Jeff F Miller; Partho Ghosh
Journal:  PLoS Biol       Date:  2008-06-03       Impact factor: 8.029

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.